MIOCARD-IA: Transparent AI for Global Cardio-Metabolic Prevention
MIOCARD-IA is an international initiative developing an advanced artificial intelligence platform designed to predict and proactively reduce the impact of cardio-metabolic diseases, including type 2 diabetes, chronic kidney disease, hypertension and MASLD. The project promotes a preventive, equitable and explainable model of population health management, integrating clinical, genetic, social and lifestyle data to better understand and address risk across diverse populations. Led by HIGIA Health Solutions (Spain), the project collaborates closely with Excellence Medical Systems Co. — Excellence Medical Services (EMS), Saudi Arabia, a strategic partner enabling real-world validation and full adaptation of the platform to the local clinical, regulatory and epidemiological context. Funded by the CDTI — “Subvencionado por el CDTI”.
Generative AI Architectures
MIOCARD-IA develops next-generation generative AI architectures capable of analyzing whole-patient profiles to deliver more accurate, personalized cardio-metabolic risk predictions.
Advanced Biomarkers & Clinical Prediction
New digital biomarkers enabling early detection and preventive intervention.
The project identifies and validates innovative clinical and computational biomarkers to support advanced prediction tasks such as hospitalization risk, cardio-renal complications, and early intervention opportunities.
Transparent & Fair AI System
Automated explainability, bias auditing and global regulatory alignment.
MIOCARD-IA builds a full transparency framework with explainability tools, fairness auditing and ethical/regulatory reporting, ensuring the platform remains safe, equitable and compliant across international healthcare settings.